A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With FGFR 1, 2, 3, or 4 Genetic Alterations

Trial Profile

A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With FGFR 1, 2, 3, or 4 Genetic Alterations

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs PRN 1371 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2016 According to Principia Biopharma media release, the company announced that initial Phase 1 clinical data for its fibroblast growth factor receptor (FGFR) 1-4 inhibitor, PRN1371, was presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
    • 07 Jan 2016 According to a Principia Biopharma media release, preliminary results from this trial are expected in 2016 and the dose expansion stage of this trial is expected to begin in the middle of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top